Trial Profile

A clinical trial evaluating Chikungunya virus vaccine for Chikungunya virus infections

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 06 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

17 Oct 2024 According to Emergex Vaccines media release, Emergex Vaccines has changed its name to Gylden Pharma Limited.
17 Nov 2023 According to an Emergex media release, the company announced that it has signed a contract with the UK Department of Health and Social Care for 1,798,109 pound. The milestone-based contract is designed such that the company will apply for MHRA regulatory submission for a Phase-1 clinical trial in the UK. The programme is intended to position Emergex for entry to the clinic by its completion, ready to begin a Phase-1 clinical trial.
30 Nov 2022 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com